老年AML患者与肿瘤医生对功能预后的期望差异
本研究在100例新诊断老年AML患者中开展预试验,随机分为UR-GOAL决策支持工具组和常规护理组,比较患者与肿瘤医生对6个月和1年功能预后的期望。
要点
- 老年AML患者对功能下降的预期远低于其肿瘤医生(6个月15% vs 51%,1年20% vs 54%)。
- 患者与医生功能预后期望一致性差,加权κ仅为0.10(6个月)和0.07(1年)。
核心结论
- 老年AML患者对未来身体功能的期望与肿瘤医生存在差异。
- UR-GOAL决策支持工具可能减少患者与医生之间临床显著的不一致。
研究设计与样本
- 预试验随机对照试验,纳入年龄≥60岁的新诊断AML成人患者,1:1随机分为UR-GOAL组或常规护理组。
- UR-GOAL包含AML教育视频、老化相关状况评估、价值观和预后意识评估。
- 100例入组患者中77例(接受8位肿瘤医生诊疗)回答了功能预后问题,患者平均年龄73岁(标准差6.8),39%为女性。
主要发现
- 患者预期功能下降的比例在6个月为15%、1年为20%,而肿瘤医生分别为51%和54%。
- 68%的患者与肿瘤医生期望不一致,加权κ在6个月为0.10、1年为0.07。
关键数值与推荐
- 患者与医生期望一致性加权κ:6个月0.10,1年0.07。
临床怎么用
- 临床中应主动识别老年AML患者对功能预后的期望,并与医生判断进行沟通比对。
- 可考虑使用UR-GOAL类决策支持工具促进患者与医生关于功能预后的讨论。
局限性
- 本研究为预试验,样本量有限(77例患者应答),结果需更大规模研究验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although older adults with cancer often prioritize maintaining physical function when making treatment decisions, whether patients and oncologists have similar expectations of future functioning remains unknown. We explored this among patients with acute myeloid leukemia (AML) and their oncologists in a pilot randomized controlled trial testing a decisional support tool (University of Rochester-Geriatric Oncology Assessment for Acute Myeloid Leukemia [UR-GOAL]). We included adults aged ≥60 years with newly diagnosed AML, randomized 1:1 to UR-GOAL (AML educational video, assessment of aging-related conditions, values, and prognostic awareness) or usual care (UC). After initiating treatment, patients and oncologists reported whether they expected the patient's physical function to decline, improve, or stay the same over the next 6 months and 1 year (functional prognosis). We estimated patient oncologist agreement using weighted κ statistics and evaluated differences by study arm. Of 100 enrolled patients, 77, who received care from 8 oncologists, responded to questions about the patient's functional prognosis. Patients had a mean age of 73 years (standard deviation, 6.8), and 39% were female. Fewer patients (15% at 6 months, 20% at 1 year) anticipated that their function would decline, compared with their oncologists (51% at 6 months, 54% at 1 year). Most patients (68%) had discordant expectations from their oncologist, with κ = 0.10 (6 months) and κ = 0.07 (1 year). However, clinically meaningful discordance (patient: maintain or improve; oncologist: decline) was less common among UR-GOAL patients vs UC (27% vs 56%; P = .010). Older adults with AML have expectations about their future physical function that differ from their oncologists. UR-GOAL may reduce this discordance. This trial was registered at www.ClinicalTrials.gov as NCT05335369.
引用
- Jensen-Battaglia M, Mortaz-Hedjri S, Blumberg R, et al. Patient and oncologist expectations of functional prognosis among older adults with acute myeloid leukemia. Blood Adv. 2026. PMID: 42275539. doi:10.1182/bloodadvances.2025019276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。